Products with Inhibitors bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2166 | Rasagiline mesylate |
| Rasagiline mesylate is a potent, selective, non-reversible MAO-B inhibitor, with neuroprotective activities, with anti-Parkinson activity. Rasagiline mesylate exhibits neuroprotective and anti-apoptotic activity against several neurotoxins in cell culture. | |
| BCN2169 | 5-Aza-2'-deoxycytidine |
| 1. Decitabine (5-Aza-2'-deoxycytidine) is a DNA methyltransferase inhibitor and an archetypal epigenetic drug for the therapy of myeloid leukemias. 2. Aza-2'-deoxycitidine exerts its anti-tumor effects in hepatocellular carcinoma(HCC) cells by inhibiting the telomerase activity. | |
| BCN2171 | Palonosetron hydrochloride |
| Palonosetron hydrochloride is the only serotonin receptor antagonist approved for prevention of delayed chemotherapy-induced nausea and vomiting (CINV) caused by moderate emetogenic chemotherapy (MEC). | |
| BCN2172 | Canertinib |
| Canertinib is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Canertinib displays anti-proliferative and pro-apoptotic effects in human myeloid leukemia cells devoid of ErbB-receptors, downregulates important signaling pathways and activates caspase-mediated intrinsic apoptosis pathway in human T-cell leukemia cells. | |
| BCN2173 | Gefitinib |
| Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively; it can reduce both cell proliferation and tumor growth of breast cancer cells expressing EGFR and/or HER2. Chronic Gefitinib treatment promotes ROS and mitochondrial dysfunction in lung cancer cells. Antioxidants may alleviate ROS-mediated resistance. | |
